Wall Street analysts predict that Valeritas Holdings, Inc. (NASDAQ:VLRX) will report $5.60 million in sales for the current fiscal quarter, according to Zacks Investment Research. Two analysts have issued estimates for Valeritas’ earnings. Valeritas reported sales of $4.80 million in the same quarter last year, which indicates a positive year-over-year growth rate of 16.7%. The business is expected to report its next quarterly earnings report on Tuesday, February 20th.
According to Zacks, analysts expect that Valeritas will report full-year sales of $5.60 million for the current fiscal year, with estimates ranging from $19.88 million to $20.00 million. For the next year, analysts forecast that the company will report sales of $27.11 million per share, with estimates ranging from $26.53 million to $27.50 million. Zacks’ sales averages are an average based on a survey of analysts that that provide coverage for Valeritas.
Valeritas (NASDAQ:VLRX) last issued its earnings results on Wednesday, November 8th. The company reported ($1.62) EPS for the quarter, topping the consensus estimate of ($1.84) by $0.22. Valeritas had a negative return on equity of 820.08% and a negative net margin of 229.55%.
Separately, ValuEngine upgraded Valeritas from a “strong sell” rating to a “sell” rating in a research report on Friday, December 1st.
Valeritas (NASDAQ VLRX) opened at $3.36 on Thursday. The company has a current ratio of 3.88, a quick ratio of 3.20 and a debt-to-equity ratio of 3.54. Valeritas has a 12-month low of $2.00 and a 12-month high of $40.00.
Valeritas, Inc is a United States-based company, which is engaged in developing and commercializing treatment solutions that contribute to clinical outcomes for patients. The Company’s portfolio includes V-Go disposable insulin delivery device, which is distributed through retail pharmacy. Its V-Go delivers insulin at a continuous preset basal rate and bolus dosing for adults with Type 2 diabetes requiring insulin.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Valeritas Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeritas and related companies with MarketBeat.com's FREE daily email newsletter.